The Fluoroquinolone Finafloxacin Protects BALB/c Mice Against an Intranasal Infection With

Francisella tularensis biothreat finafloxacin in vivo efficacy therapeutic

Journal

Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977

Informations de publication

Date de publication:
2019
Historique:
received: 14 02 2019
accepted: 09 04 2019
entrez: 24 5 2019
pubmed: 24 5 2019
medline: 24 5 2019
Statut: epublish

Résumé

The efficacy of the novel fluoroquinolone finafloxacin was evaluated as a potential therapeutic

Identifiants

pubmed: 31118924
doi: 10.3389/fmicb.2019.00904
pmc: PMC6504792
doi:

Types de publication

Journal Article

Langues

eng

Pagination

904

Références

Antimicrob Agents Chemother. 1999 May;43(5):1298-300
pubmed: 10223958
Clin Infect Dis. 2000 Aug;31(2):623
pubmed: 10987739
JAMA. 2001 Jun 6;285(21):2763-73
pubmed: 11386933
Clin Infect Dis. 2001 Aug 15;33(4):573-6
pubmed: 11462198
Clin Microbiol Rev. 2002 Oct;15(4):631-46
pubmed: 12364373
J Clin Microbiol. 2003 Jan;41(1):50-7
pubmed: 12517824
Microb Pathog. 2003 May;34(5):239-48
pubmed: 12732472
Nat Genet. 2005 Feb;37(2):153-9
pubmed: 15640799
Infection. 2005 Dec;33 Suppl 2:55-70
pubmed: 16518713
FEMS Immunol Med Microbiol. 2007 Apr;49(3):315-23
pubmed: 17316369
Microb Pathog. 2008 Feb;44(2):164-8
pubmed: 17904793
Expert Rev Anti Infect Ther. 2008 Apr;6(2):231-40
pubmed: 18380605
Antimicrob Agents Chemother. 2010 Apr;54(4):1613-5
pubmed: 20100879
Int J Antimicrob Agents. 2011 Jul;38(1):52-9
pubmed: 21596526
Front Microbiol. 2011 Feb 01;2:9
pubmed: 21687406
Antimicrob Agents Chemother. 2011 Sep;55(9):4394-7
pubmed: 21709094
Microbiology. 2011 Nov;157(Pt 11):3172-9
pubmed: 21852349
Antimicrob Agents Chemother. 2012 Oct;56(10):5406-8
pubmed: 22850512
Front Cell Infect Microbiol. 2014 Mar 13;4:35
pubmed: 24660164
Front Cell Infect Microbiol. 2014 Mar 18;4:36
pubmed: 24672776
Front Cell Infect Microbiol. 2014 Mar 28;4:40
pubmed: 24734221
Drugs. 2015 Apr;75(6):687-93
pubmed: 25808831
PLoS Pathog. 2015 Dec 03;11(12):e1005208
pubmed: 26633893
J Antimicrob Chemother. 2017 Apr 1;72(4):1258-1260
pubmed: 28039270
Front Microbiol. 2017 Feb 06;8:91
pubmed: 28220110
Antimicrob Agents Chemother. 2017 Jun 27;61(7):
pubmed: 28438936
Pharmacotherapy. 2018 Feb;38(2):217-234
pubmed: 29236288
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29339393
Antimicrob Agents Chemother. 2018 Mar 27;62(4):
pubmed: 29339395
Front Cell Infect Microbiol. 2018 Apr 06;8:115
pubmed: 29682484
Chemotherapy. 1988;34(4):308-14
pubmed: 3208548
Medicine (Baltimore). 1985 Jul;64(4):251-69
pubmed: 3892222
Semin Respir Infect. 1997 Mar;12(1):61-7
pubmed: 9097380

Auteurs

Kay B Barnes (KB)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.

Karleigh A Hamblin (KA)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.

Mark I Richards (MI)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.

Thomas R Laws (TR)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.

Andreas Vente (A)

MerLion Pharmaceuticals, Berlin, Germany.

Helen S Atkins (HS)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.
University of Exeter, Exeter, United Kingdom.
London School of Hygiene & Tropical Medicine, London, United Kingdom.

Sarah V Harding (SV)

Defence Science and Technology Laboratory, Salisbury, United Kingdom.

Classifications MeSH